ClinicalTrials.gg
CompletedNCT04936308SOLSTICEUpdated Nov 3, 2026Results posted

Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent

A Phase 3 interventional study of Guselkumab and Placebo in Arthritis, Psoriatic, sponsored by Janssen Research & Development, LLC. Completed at 169 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing guselkumab in Arthritis, Psoriatic — 5 open to participants now, 8 under way, 3 of them phase 3. guselkumab · Arthritis, Psoriatic.

Enrollment
3rd of 14
453 · median 173
Started
2021
with 3 others
Phase 3
7 of 14
1 open now
Registered
7th of 14
by date
Lead sponsor
9 of 14
Janssen Research & Development, LLC

Among the 14 studies testing guselkumab in Arthritis, Psoriatic, this one is the 3rd largest by enrollment, is one of 4 that started in 2021, is one of 7 in phase 3, and was the 7th registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

5 of the 14 studies testing guselkumab in Arthritis, Psoriatic are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About guselkumab

guselkumab: first FDA approval 2017 (TREMFYA), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing guselkumab in Arthritis, Psoriatic, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate response (IR) and/or intolerance to a prior anti-tumor necrosis factor (TNF) by assessing the reduction in signs and symptoms of PsA.

Read the detailed description

PsA is a chronic, immune-mediated inflammatory disease characterized by peripheral joint inflammation, enthesitis, dactylitis, axial disease, and the skin lesions associated with psoriasis. Guselkumab is a fully human monoclonal antibody (mAb) that binds to p19 protein subunit of interleukin (IL)-23 and blocks the binding of extracellular IL-23 to the cell surface IL-23 receptor, inhibiting IL-23 specific intracellular signaling, subsequent activation, and cytokine production. The primary hypothesis of this study is that guselkumab is superior to placebo as assessed by the proportion of participants who had an inadequate response (IR) and/or intolerance to one prior anti-tumor necrosis factor (anti-TNF) achieving an American College of Rheumatology 20 (ACR 20) response at Week 24. This study will consist of a screening phase (up to 6 weeks), blinded treatment phase (approximately up to 2 years), which includes a placebo-controlled period from Week 0 to Week 24, and an active-controlled treatment phase from Week 24 to Week 100, and safety follow-up phase (Week 112). Safety assessments will include physical examinations, vital signs, height, weight, electrocardiograms, and clinical safety laboratory assessments. The total duration of the study will be up to 118 weeks.

03

Conditions studied

  • Arthritis, Psoriatic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of active psoriatic arthritis (PsA) for at least 6 months before the first administration of study agent and meet Classification criteria for Psoriatic Arthritis (CASPAR) at screening
  • Have active PsA as defined by: at least 3 swollen joints and at least 3 tender joints at screening and at baseline; and C-reactive protein (CRP) greater than or equal to (>=) 0.3 milligrams per deciliter (mg/dL) at screening from the central laboratory
  • Have at least one of the following PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
  • Have active plaque psoriasis, with at least one psoriatic plaque of >= 2 centimeters (cm) diameter and/or nail changes consistent with psoriasis, or documented history of plaque psoriasis
  • Have an inadequate response and/or intolerance to anti-tumor necrosis factor alpha (TNF alpha) therapy, defined as presence of active PsA despite previous treatment with one prior anti-TNF alpha agent

Exclusion criteria

Exclusion Criteria:

  • Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy in the treatment of PsA, including but not limited to rheumatoid arthritis, ankylosing spondylitis/nonradiographic axial spondyloarthritis, systemic lupus erythematosus, or Lyme disease
  • Has received more than 1 prior anti-tumor necrosis factor (TNF) alpha agent (or biosimilars)
  • Has ever received Janus kinase (JAK) inhibitor including but not limited to tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, upadacitinib or any other JAK inhibitor
  • Has received any systemic (example, azathioprine, cyclosporine, 6 thioguanine, mercaptopurine, mycophenolate mofetil, hydroxyurea, tacrolimus) within 4 weeks of the first administration of study intervention
  • Has known allergies, , or intolerance to guselkumab or its
  • Has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection (example, bronchiectasis), recurrent urinary tract infection (example, recurrent pyelonephritis or chronic non-remitting cystitis), fungal infection (example, mucocutaneous candidiasis), or open, draining, or infected skin wounds or ulcers
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
453 participants (actual)

Study arms

  • Experimental
    Group 1: Guselkumab and Placebo

    Participants will receive guselkumab and placebo subcutaneously (SC) to maintain the blind.

    Drug: Guselkumab · Drug: Placebo

  • Experimental
    Group 2: Guselkumab

    Participants will receive guselkumab SC.

    Drug: Guselkumab

  • Experimental
    Group 3: Placebo Followed by Guselkumab

    Participants will receive placebo SC and will cross over to receive guselkumab SC.

    Drug: Guselkumab · Drug: Placebo

Interventions

  • Participants will receive guselkumab as SC injection.

    Also known as: Tremfya, CNTO1959

  • DrugPlacebo

    Participants will receive matching placebo as SC injection.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

    ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

    Time frame: At Week 24

Secondary outcomes

  1. Percentage of Participants Who Achieved a Psoriasis Response of Investigator's Global Assessment (IGA) Psoriasis Score of 0 or 1 and >=2 Grade Reduction From Baseline at Week 24 Among the Participants With >=3 Percent(%) Body Surface Area (BSA)

    A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and greater than equal to (\>=2) grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

    Time frame: At Week 24

  2. Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

    PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.

    Time frame: At Week 24

  3. Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 24

    The HAQ-DI is a 20-question instrument that assesses the degree of difficulty a participant has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living), each scored from 0 (no difficulty) to 3 (inability to perform a task in that area). Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

    Time frame: Baseline (pre dose Week 0) and Week 24

  4. Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

    SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

    Time frame: Baseline (pre dose Week 0) and Week 24

  5. Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24

    The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

    Time frame: Baseline (pre dose Week 0) and Week 24

  6. Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 24

    MDA is a measure that defines a satisfactory state of disease activity that includes 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis). Participants were classified as achieving MDA if they fulfilled 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).

    Time frame: At Week 24

  7. Percentage of Participants Who Achieved ACR 20 Response at Week 16

    ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

    Time frame: At Week 16

  8. Percentage of Participants Who Achieved ACR 50 Response at Week 16

    ACR 50 response: \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

    Time frame: At Week 16

  9. Percentage of Participants Who Achieved ACR 50 Response at Week 24

    ACR 50 response: \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

    Time frame: At Week 24

  10. Percentage of Participants Who Achieved ACR 70 Response at Week 24

    ACR 70 response: \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

    Time frame: At Week 24

  11. Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)

    Time frame: From first administration of study drug (Week 0) up to Week 112

  12. Percentage of Participants With Treatment Emergent Serious Adverse Events (TESAEs)

    Time frame: From first administration of study drug (Week 0) up to Week 112

  13. Percentage of Participants With Treatment Emergent Related AEs (TERAEs)

    Time frame: From first administration of study drug (Week 0) up to Week 112

  14. Treatment Emergent AEs Leading to Discontinuation of Study Intervention

    Time frame: From first administration of study drug (Week 0) up to Week 112

  15. Percentage of Participants With Infections

    Time frame: From first administration of study drug (Week 0) up to Week 112

  16. Percentage of Participants With Injection-site Reactions

    Time frame: From first administration of study drug (Week 0) up to Week 112

  17. Percentage of Participants With Infusion Related Reactions

    Time frame: From first administration of study drug (Week 0) up to Week 112

  18. Number of Participants With Post-baseline Laboratory Abnormalities With Maximum Toxicity Grade Greater Than or Equal to >=3 Based on Common Terminology Criteria for Adverse Events (CTCAE)

    Time frame: From first administration of study drug (Week 0) up to Week 112

  19. Serum Guselkumab Concentration Over Time

    Serum concentrations of guselkumab over time was reported.

    Time frame: At Weeks 0, 4, 8, 12, 16, 20,and 24

  20. Number of Participants With Antibodies to Guselkumab

    Number of participants with antibodies to guselkumab (ADA) were reported. A validated immunoassay was used to detect ADA.

    Time frame: Baseline (pre dose Week 0) up to Week 24

07

Results

Posted Dec 8, 2025

Participant flow

Participant flow — Overall Study
MilestonePlacebo Followed by Guselkumab 100 mgGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Started150152151
Full analysis set150151150
Completed138144141
Not completed12810
Withdrew: Death001
Withdrew: Withdrawal by subject630
Withdrew: Excluded from analysis (enrolled and dosed at 2 sites)011
Withdrew: Completed protocol-required follow-up122
Withdrew: Discontinued study intervention and were being followed224
Withdrew: Other302

Outcome measures

PrimaryPercentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24

ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

Time frame:
At Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 24
Percentage of participantsPlacebo Followed by Guselkumab 100 mgGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved an American College of Rheumatology (ACR) 20 Response at Week 2435.963.060.9
SecondaryPercentage of Participants Who Achieved a Psoriasis Response of Investigator's Global Assessment (IGA) Psoriasis Score of 0 or 1 and >=2 Grade Reduction From Baseline at Week 24 Among the Participants With >=3 Percent(%) Body Surface Area (BSA)

A psoriasis IGA response was defined as an IGA score of 0 (cleared) or 1 (minimal) and greater than equal to (\>=2) grade reduction from baseline in the IGA psoriasis score. The IGA documents the investigator's assessment of the patient's psoriasis and lesions are graded for induration, erythema and scaling, each using a 5 point scale: 0 (no evidence), 1 (minimal), 2 (mild), 3 (moderate), and 4 (severe). The IGA score of psoriasis was based upon the average of induration, erythema and scaling scores. The participant's psoriasis was assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved a Psoriasis Response of Investigator's Global Assessment (IGA) Psoriasis Score of 0 or 1 and >=2 Grade Reduction From Baseline at Week 24 Among the Participants With >=3 Percent(%) Body Surface Area (BSA)
percentage of participantsPlacebo Followed by Guselkumab 100 mgGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved a Psoriasis Response of Investigator's Global Assessment (IGA) Psoriasis Score of 0 or 1 and >=2 Grade Reduction From Baseline at Week 24 Among the Participants With >=3 Percent(%) Body Surface Area (BSA)18.860.756.8
SecondaryPercentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline

PASI is a tool to assess and grade severity of psoriasis and response to therapy. In PASI, body is divided into 4 areas: head, trunk, upper extremities, lower extremities. Each area was assessed separately for percentage of area involved and translated to numeric score ranging from 0 (no involvement) to 6 (90 to 100% involvement), and for erythema, induration, and scaling, each rated on scale of 0 to 4 that is none to maximum severtiy. PASI numeric score range from 0 (no psoriasis) to 72. Higher scores indicate more severe disease. A PASI 90 response: \>=90% improvement in PASI score from baseline.

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline
percentage of participantsPlacebo Followed by Guselkumab 100 mgGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved Psoriasis Area and Severity Index (PASI) 90 Response at Week 24 Among the Participants With >=3% BSA Psoriatic Involvement and an IGA Score of >=2 (Mild) at Baseline12.547.654.9
SecondaryChange From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 24

The HAQ-DI is a 20-question instrument that assesses the degree of difficulty a participant has in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living), each scored from 0 (no difficulty) to 3 (inability to perform a task in that area). Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty. Lower scores are indicative of better functioning. Negative change from baseline indicates improvement of physical function.

Time frame:
Baseline (pre dose Week 0) and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 24
units on a scalePlacebo Followed by Guselkumab 100 mgGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Health Assessment Questionnaire Disability Index (HAQ-DI) Score at Week 24-0.2359 (-0.3200 to -0.1519)-0.3955 (-0.4787 to -0.3122)-0.4159 (-0.5006 to -0.3313)
SecondaryChange From Baseline in 36-item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24

SF-36 is a multi-domain instrument with 36 items to evaluate the health status and quality of life. It included 8 subscales (physical functioning, physical role functioning, bodily pain, general health perception, vitality, social functioning, emotional role functioning, and mental health), which yielded a Physical Component Summary (PCS) with score range 0-100 (higher score-better quality of life) and a Mental Component Summary (MCS) with score range 0-100 (higher score-better quality of life) in addition to subscale scores. The PCS scores are normalized to a mean of 50 and standard deviations of 10, based upon general US population norms. A positive change indicates improvement while a negative change indicates worsening of health status and quality of life.

Time frame:
Baseline (pre dose Week 0) and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 24
units on a scalePlacebo Followed by Guselkumab 100 mgGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in 36-item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score at Week 243.705 (2.464 to 4.946)6.986 (5.758 to 8.213)7.027 (5.772 to 8.282)
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24

The FACIT-Fatigue is a questionnaire that assesses self-reported tiredness, weakness, and difficulty conducting usual activities due to fatigue. The subscale consists 13-item instrument to measure fatigue. Each of the 13 items has a set of five response categories: Not at all (=0), A little bit (=1), Somewhat (=2), Quite a bit (=3) and Very much (=4). A total FACIT-Fatigue subscale score was calculated as the sum of the 13 item scores (reserved scores \[4 - score\]) and ranges from 0 to 52, with a higher score indicating less fatigue. Positive changes from baseline indicate improvement of fatigue. Items were reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatigue.

Time frame:
Baseline (pre dose Week 0) and Week 24
Reported as:
Least squares mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 24
units on a scalePlacebo Followed by Guselkumab 100 mgGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Change From Baseline in Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Score at Week 243.9 (2.5 to 5.3)7.8 (6.4 to 9.2)8.4 (7.0 to 9.9)
SecondaryPercentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 24

MDA is a measure that defines a satisfactory state of disease activity that includes 5 domains of PsA (joint symptoms, skin psoriasis, patient's perspective of pain and disease activity on arthritis and psoriasis, physical function and enthesitis). Participants were classified as achieving MDA if they fulfilled 5 of the following 7 criteria at that visit: Tender joint count (68 joints)\<=1, Swollen joint count (66 joints) \<=1, Psoriasis activity and severity index \<=1, Patient's Assessment of Pain \<=15 on a 100-unit VAS, Patient's Global Assessment of Disease Activity (arthritis and psoriasis) \<=20 on a 100-unit VAS, HAQ-DI score \<=0.5, and Tender entheseal points \<= 1 (LEI index score \<= 1).

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 24
percentage of participantsPlacebo Followed by Guselkumab 100 mgGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved Minimal Disease Activity (MDA) at Week 245.624.820.4
SecondaryPercentage of Participants Who Achieved ACR 20 Response at Week 16

ACR 20 response: \>=20% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=20% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 20 Response at Week 16
percentage of participantsPlacebo Followed by Guselkumab 100 mgGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved ACR 20 Response at Week 1630.757.553.2
SecondaryPercentage of Participants Who Achieved ACR 50 Response at Week 16

ACR 50 response: \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

Time frame:
At Week 16
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 50 Response at Week 16
percentage of participantsPlacebo Followed by Guselkumab 100 mgGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved ACR 50 Response at Week 1610.128.825.0
SecondaryPercentage of Participants Who Achieved ACR 50 Response at Week 24

ACR 50 response: \>=50% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=50% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

Time frame:
At Week 24
Reported as:
Number · percantage of participants
Percentage of Participants Who Achieved ACR 50 Response at Week 24
percantage of participantsPlacebo Followed by Guselkumab 100 mgGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved ACR 50 Response at Week 2412.732.933.3
SecondaryPercentage of Participants Who Achieved ACR 70 Response at Week 24

ACR 70 response: \>=70% improvement from baseline in both swollen joint count (66 joints) and tender joint count (68 joints), and \>=70% improvement from baseline in 3 of 5 assessments: patient's assessment of pain using visual analog scale (VAS; 0-100 mm, 0=no pain and 100=worst possible pain), patient's global assessment of disease activity (arthritis, VAS; 0-100 mm, 0=excellent and 100= poor), physician's global assessment of disease activity (VAS; 0-100 mm, 0=no arthritis activity and 100=extremely active arthritis), patient's assessment of physical function measured by Disability Index of Health Assessment Questionnaire (HAQ-DI; 20-question instrument assessing 8 functional areas; range: 0-3, 0= no difficulty, 3= inability to perform task in that area), and CRP.

Time frame:
At Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved ACR 70 Response at Week 24
percentage of participantsPlacebo Followed by Guselkumab 100 mgGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Percentage of Participants Who Achieved ACR 70 Response at Week 242.117.819.0
SecondaryPercentage of Participants With Treatment Emergent Adverse Events (TEAEs)
Time frame:
From first administration of study drug (Week 0) up to Week 112

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Treatment Emergent Serious Adverse Events (TESAEs)
Time frame:
From first administration of study drug (Week 0) up to Week 112

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Treatment Emergent Related AEs (TERAEs)
Time frame:
From first administration of study drug (Week 0) up to Week 112

Results for this outcome have not been posted.

SecondaryTreatment Emergent AEs Leading to Discontinuation of Study Intervention
Time frame:
From first administration of study drug (Week 0) up to Week 112

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Infections
Time frame:
From first administration of study drug (Week 0) up to Week 112

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Injection-site Reactions
Time frame:
From first administration of study drug (Week 0) up to Week 112

Results for this outcome have not been posted.

SecondaryPercentage of Participants With Infusion Related Reactions
Time frame:
From first administration of study drug (Week 0) up to Week 112

Results for this outcome have not been posted.

SecondaryNumber of Participants With Post-baseline Laboratory Abnormalities With Maximum Toxicity Grade Greater Than or Equal to >=3 Based on Common Terminology Criteria for Adverse Events (CTCAE)
Time frame:
From first administration of study drug (Week 0) up to Week 112

Results for this outcome have not been posted.

SecondarySerum Guselkumab Concentration Over Time

Serum concentrations of guselkumab over time was reported.

Time frame:
At Weeks 0, 4, 8, 12, 16, 20,and 24
Reported as:
Mean · micrograms/milliliters (mcg/mL)
Serum Guselkumab Concentration Over Time
micrograms/milliliters (mcg/mL)Guselkumab 100 mg q8wGuselkumab 100 mg q4w
Week 00.00 ± 0.0030.00 ± 0.004
Week 42.22 ± 1.1622.32 ± 1.331
Week 83.23 ± 1.7893.16 ± 1.740
Week 121.10 ± 0.7453.45 ± 2.038
Week 162.79 ± 1.4363.58 ± 2.119
Week 200.90 ± 0.6033.61 ± 2.013
Week 242.71 ± 1.3473.79 ± 2.288
SecondaryNumber of Participants With Antibodies to Guselkumab

Number of participants with antibodies to guselkumab (ADA) were reported. A validated immunoassay was used to detect ADA.

Time frame:
Baseline (pre dose Week 0) up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Antibodies to Guselkumab
ParticipantsGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Number of Participants With Antibodies to Guselkumab617

Adverse events

Collected over From first administration of study drug (Week 0) up to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/149 (0%)6/149 (4%)18/149 (12.1%)
Guselkumab 100 mg q8w0/151 (0%)4/151 (2.6%)24/151 (15.9%)
Guselkumab 100 mg q4w1/150 (0.7%)2/150 (1.3%)16/150 (10.7%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
Atrial FibrillationCardiac disorders1/1490/1510/150
GastritisGastrointestinal disorders1/1490/1510/150
Allergy to Arthropod StingImmune system disorders1/1490/1510/150
LaryngitisInfections and infestations1/1490/1510/150
PyelonephritisInfections and infestations1/1490/1510/150
Abnormal Uterine BleedingReproductive system and breast disorders1/1490/1510/150
Myocardial InfarctionCardiac disorders0/1490/1511/150
Myasthenia GravisNervous system disorders0/1490/1511/150
ColitisGastrointestinal disorders0/1491/1510/150
Muscle SpasmsMusculoskeletal and connective tissue disorders0/1491/1510/150
Most frequent other events
Most frequent other events
EventPlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4w
NasopharyngitisInfections and infestations8/1499/1515/150
HeadacheNervous system disorders3/1499/1514/150
Covid-19Infections and infestations8/1498/1517/150

Baseline characteristics

Full analysis set (FAS) included all participants who were randomized in the study and included in the analyses.

Age, Continuous
Age, Continuous(Years)PlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
Mean49.2 ± 12.5951.9 ± 12.9150.6 ± 13.2950.6 ± 12.95
Age, Customized
Age, Customized(Participants)PlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
Adults (18-64 years)132126127385
From 65 to 84 years18252366
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
Female857775237
Male657475214
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
Hispanic or Latino22181858
Not Hispanic or Latino127128132387
Unknown or Not Reported1506
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
American Indian or Alaska Native2013
Asian1034
Native Hawaiian or Other Pacific Islander0000
Black or African American46515
White141143141425
More than one race0000
Unknown or Not Reported2204
Region of Enrollment
Region of Enrollment(Participants)PlaceboGuselkumab 100 mg q8wGuselkumab 100 mg q4wTotal
ARGENTINA79824
BULGARIA15172153
CZECH REPUBLIC1010727
HUNGARY87924
ISRAEL35210
MALAYSIA1023
POLAND394238119
RUSSIAN FEDERATION1013528
SPAIN2147
TURKEY54413
UKRAINE18141850
UNITED STATES32293293
08

Study locations

169 sites
  • Arthritis Associates
    Mountain Brook, Alabama 35223, United States
  • Arizona Arthritis and Rheumatology Research PLLC 2
    Avondale, Arizona 85392, United States
  • Arizona Arthritis and Rheumatology Research PLLC 3
    Flagstaff, Arizona 86001-6218, United States
  • Arizona Arthritis and Rheumatology Research PLLC
    Mesa, Arizona 85210, United States
  • Arizona Arthritis and Rheumatology Research PLLC 1
    Phoenix, Arizona 85032, United States
  • Arizona Arthritis and Rheumatology Associates
    Sun City, Arizona 85351, United States
  • Southern Arizona VA Healthcare System
    Tucson, Arizona 85723, United States
  • Unity Health-White County Medical Center
    Searcy, Arkansas 72143, United States
  • Newport Huntington Medical Group
    Huntington Beach, California 92648, United States
  • Medvin Clinical Research 2
    Thousand Oaks, California 91360, United States
  • Medvin Clinical Research
    Tujunga, California 91042, United States
  • Clinical Research Center of Connecticut
    Danbury, Connecticut 06810, United States
  • Bay Pines VA Healthcare System
    Bay Pines, Florida 33744, United States
  • Clinical Research of West Florida
    Clearwater, Florida 33765, United States
  • Omega Research Consultants
    DeBary, Florida 32713, United States
  • Advanced Clinical Research of Orlando
    Ocoee, Florida 34761, United States
  • Integral Rheumatology And Immunology Specialists
    Plantation, Florida 33324, United States
  • Clinical Research of West Florida 1
    Tampa, Florida 33606, United States
  • Florida Medical Clinic, P.A.
    Zephyrhills, Florida 33542, United States
  • Great Lakes Clinical Trials
    Chicago, Illinois 60640, United States
  • Clinic of Robert Hozman
    Skokie, Illinois 60076, United States
  • The Arthritis and Diabetes Clinic
    Monroe, Louisiana 71203, United States
  • Johns Hopkins University
    Baltimore, Maryland 21287, United States
  • Klein And Associates M D P A
    Hagerstown, Maryland 21740, United States
  • Great Lakes Center of Rheumatology
    Lansing, Michigan 48911, United States
  • Arthritis and Rheumatology Center of MI
    Okemos, Michigan 48864, United States
  • Clinical Research Institute of Michigan, LLC
    Saint Clair Shores, Michigan 48081, United States
  • St. Paul Rheumatology P A
    Eagan, Minnesota 55121, United States
  • Arthritis Consultants
    St Louis, Missouri 63141, United States
  • Arthritis Rheumatic And Back Disease Associates
    Voorhees Township, New Jersey 08043, United States
  • Albuquerque Center for Rheumatology
    Albuquerque, New Mexico 87102, United States
  • Arthritis and Osteoperosis Associates of New Mexico
    Las Cruces, New Mexico 88011, United States
  • Buffalo Rheumatology and Medicine PLLC
    Orchard Park, New York 14127, United States
  • DJL Clinical Research, PLLC
    Charlotte, North Carolina 28211, United States
  • STAT Research, Inc.
    Vandalia, Ohio 45377, United States
  • Health Research of Oklahoma
    Oklahoma City, Oklahoma 73103, United States
  • Rheumatology Associates of Oklahoma
    Oklahoma City, Oklahoma 73116, United States
  • Dr. Ramesh Gupta
    Memphis, Tennessee 38119, United States
  • Precision Comprehensive Clinical Research Solutions
    Colleyville, Texas 76034, United States
  • Adriana Pop Moody MD Clinic PA
    Corpus Christi, Texas 78404, United States
  • Metroplex Clinical Research Center
    Dallas, Texas 75231, United States
  • Precision Comprehensive Clinical Research Solutions 1
    Fort Worth, Texas 76107, United States
  • West Texas Clinical Research
    Lubbock, Texas 79424, United States
  • Southwest Rheumatology Research LLC
    Mesquite, Texas 75150, United States
  • Texas Rheumatology Care
    Plano, Texas 75024, United States
  • Advanced Rheumatology of Houston
    The Woodlands, Texas 77382, United States
  • DM Clinical Research
    Tomball, Texas 77375, United States
  • Arthritis And Osteoporosis Clinic
    Waco, Texas 76710, United States
  • Arthritis Northwest PLLC 1
    Spokane, Washington 99204, United States
  • Rheumatology and Pulmonary Clinic
    Beckley, West Virginia 25801, United States
  • Cosultorios Reumatologógicos Pampa
    Buenos Aires, 1428, Argentina
  • OMI
    Buenos Aires, C1015ABO, Argentina
  • CIPREC
    Buenos Aires, C1061AAS, Argentina
  • Centro Privado de Medicina Familiar
    Buenos Aires, C1417EYG, Argentina
  • Hospital Central Militar Cirujano Mayor Dr Cosme Argerich
    Buenos Aires, C1426BOS, Argentina
  • Instituto de Reumatología Mendoza
    Mendoza, M5631AHF, Argentina
  • Centro de Investigaciones Medicas Tucuman
    San Miguel de Tucumán, T4000AXL, Argentina
  • Southern Clinical Research
    Hobart, 7000, Australia
  • Liverpool Hospital
    Liverpool, 2170, Australia
  • Skin Health Institute Inc.
    Melbourne, 3053, Australia
  • Eastern Health - Box Hill Hospital
    Melbourne, 3128, Australia
  • UMHAT 'Dr. Georgi Stranski', EAD
    Pleven, 5804, Bulgaria
  • Medical Center Unimed Plovdiv
    Plovdiv, 4001, Bulgaria
  • UMHAT Kaspela
    Plovdiv, 4001, Bulgaria
  • Diagnosis-consulting centre-1
    Rousse, 7002, Bulgaria
  • Military Medical Academy
    Sofia, 1606, Bulgaria
  • UMHAT St. Ivan Rilski
    Sofia, 1612, Bulgaria
  • ASIMP Rheumatology Centre St Irina EOOD
    Sofia, 1750, Bulgaria
  • University Multiprofile Hospital Sofiamed Sofia
    Sofia, 1770, Bulgaria
  • Medical Centre Synexus
    Sofia, 1794, Bulgaria
  • RHEUMA s r o
    Břeclav, 690 02, Czechia
  • L K N Arthrocentrum
    Hlučín, 748 01, Czechia
  • MUDr Rosypalova s r o
    Ostrava, 70800, Czechia
  • Arthrohelp S.R.O.
    Pardubice, 53002, Czechia
  • Revmatologicky ustav
    Prague, 128 50, Czechia
  • Medical Plus S R O
    Uherské Hradiště, 68601, Czechia
  • PV Medical S R O
    Zlín, 76001, Czechia
  • Betegapolo Irgalmas Rend Budai Irgalmasrendi Korhaz
    Budapest, 1027, Hungary
  • Uno Medical Trials Ltd.
    Budapest, 1152, Hungary
  • Debreceni Egyetem, Kenézy Gyula Egyetemi Oktatókórház
    Debrecen, 4031, Hungary
  • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaz
    Gyula, 5700, Hungary
  • Pest Megyei Flor Ferenc Korhaz
    Kistarcsa, 2143, Hungary
  • Szegedi Tudományegyetem, ÁOK, Szent-Györgyi Albert Klinikai Központ
    Szeged, 6725, Hungary
  • Fejer Varmegyei Szent Gyorgy Egyetemi Oktatokorhaz
    Székesfehérvár, H-8000, Hungary
  • Vital Medical Center Orvosi es Fogaszati Kozpont
    Veszprém, 8200, Hungary
  • Bnai Zion Medical Center
    Haifa, 31048, Israel
  • Rambam Health Care Campus
    Haifa, 3109601, Israel
  • Carmel Medical Center
    Haifa, 34362, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Sheba Medical Center
    Ramat Gan, 5265601, Israel
  • Hospital Selayang
    Batu Caves, 68100, Malaysia
  • Hospital Pulau Pinang
    George Town, 10990, Malaysia
  • Hospital Raja Permaisuri Bainun
    Ipoh, 30450, Malaysia
  • Hospital Tuanku Jaafar
    Seremban, 70300, Malaysia
  • Nzoz Bif Med
    Bytom, 41 902, Poland
  • Centrum Kliniczno Badawcze
    Elblag, 82-300, Poland
  • Malopolskie Badania Kliniczne Sp z o o
    Krakow, 30 002, Poland
  • Malopolskie Centrum Kliniczne
    Krakow, 30 149, Poland
  • Centrum Medyczne Promed
    Krakow, 31-513, Poland
  • Dermed Centrum Medyczne Sp z o o
    Lodz, 90-265, Poland

Showing the first 100 of 169 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Shao J, Krol Y, Gottlieb AB. Efficacy and Safety of Guselkumab in Participants With Active Psoriatic Arthritis After Inadequate Response to One Prior Tumor Necrosis Factor Inhibitor: Week-24 Results of a Phase 3, Randomized, Placebo-Controlled Study. Arthritis Rheumatol. 2026 Aug;78(8):1674-1686. doi: 10.1002/art.70092. Epub 2026 Apr 16. PubMed 41670439 ↗
  • Ogdie A, Merola JF, Mease PJ, Ritchlin CT, Scher JU, Lafferty KP, Chan D, Chakravarty SD, Langholff W, Wang Y, Choi O, Krol Y, Gottlieb AB. Efficacy and safety of guselkumab in patients with active psoriatic arthritis who had inadequate efficacy and/or intolerance to one prior tumor necrosis factor inhibitor: study protocol for SOLSTICE, a phase 3B, multicenter, randomized, double-blind, placebo-controlled study. BMC Rheumatol. 2024 May 21;8(1):20. doi: 10.1186/s41927-024-00386-7. PubMed 38773563 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.janssen.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2021 to primary completion in Oct 2024, 37 months.

Results were first posted in Dec 2025, 1 year 1 month after primary completion.

Of 68 industry-sponsored phase 3 interventional studies under Arthritis, Psoriatic, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's 37 months is above that.

Counting every sponsor, half of 74 studies reached it within 28 months; a quarter within 19 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2021
First posted
Jun 23, 2021
StartActual
Sep 28, 2021
Primary completionActual
Oct 28, 2024
CompletionActual
Jul 2, 2026
Results first posted
Dec 8, 2025
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 41670439 ↗
Nov 3, 2026
Show all 1 update
  1. Nov 3, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 41670439 ↗
    + 2 other changes: verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04936308
Responsible party
Sponsor
First posted
Jun 23, 2021
Start date
Sep 28, 2021
Primary completion
Oct 28, 2024
Completion
Jul 2, 2026
Results posted
Dec 8, 2025
Last update
Nov 3, 2026

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Guselkumab

Start the discussion